RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX

RWA Wealth Partners LLC decreased its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 66.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 86,516 shares of the company’s stock after selling 174,500 shares during the period. RWA Wealth Partners LLC owned 0.66% of Avalo Therapeutics worth $1,100,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Velan Capital Investment Management LP grew its stake in shares of Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after buying an additional 43,000 shares during the last quarter. Patient Square Capital LP bought a new stake in Avalo Therapeutics in the third quarter worth $1,271,000. Aberdeen Group plc bought a new stake in Avalo Therapeutics in the third quarter worth $925,000. Vanguard Group Inc. grew its stake in shares of Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after acquiring an additional 525,696 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after acquiring an additional 95,000 shares in the last quarter. 87.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on AVTX shares. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Avalo Therapeutics in a research note on Thursday, January 15th. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.88.

Avalo Therapeutics Trading Up 4.7%

Shares of AVTX stock opened at $17.64 on Friday. Avalo Therapeutics, Inc. has a 12-month low of $3.39 and a 12-month high of $20.72. The stock has a market capitalization of $326.52 million, a P/E ratio of -3.29 and a beta of 0.88. The firm’s 50 day moving average is $16.11 and its 200 day moving average is $14.85.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.